Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for G6PD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | G6PD Recombinant Protein (Wild-Type & Clinical Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed. |
View G6PD Products |
| Gene Delivery | G6PD Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and metabolic flux analysis. |
View G6PD Products |
| Benchmark Ab | Anti-G6PD Recombinant Antibody Recombinant positive control for Western Blot, IHC, and ELISA validation. |
View G6PD Products |
| Validator | G6PD siRNA Set For target knockdown verification and metabolic phenotype validation. |
View G6PD Products |
| Related Target A | 6PGD (6-Phosphogluconate Dehydrogenase) Parallel enzyme in the pentose phosphate pathway; critical for selectivity counter-screening. |
View 6PGD Products |
| Related Target B | Nrf2 (NFE2L2) Master transcriptional regulator of antioxidant response; upstream driver of G6PD expression. |
View Nrf2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against homologous dehydrogenases | High-purity human 6PGD and related dehydrogenase panels strictly verified by mass spectrometry. |
| Assay interference from enzyme tags | His-tagged and Tag-free G6PD formulations available to eliminate assay artifacts in biochemical screening. |
| Lack of controls for target knockdown | Sequence-verified G6PD siRNA sets included for functional validation in cancer cell lines. |
| Batch-to-batch enzymatic variability | Strictly controlled endotoxin levels (<1 EU/µg) and single-band purity (>95% by SDS-PAGE) to ensure reproducible kinetics. |
Live G6PD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for G6PD therapeutics is intensifying, with major players shifting focus from traditional metabolic profiling to targeted oncology therapeutics. G6PD (Glucose-6-phosphate dehydrogenase) serves as the rate-limiting enzyme of the pentose phosphate pathway (PPP), making it a crucial metabolic vulnerability in rapidly proliferating cancer cells. As first-generation therapies and covalent inhibitors reach pre-clinical and early clinical validation, the next wave of R&D is targeting selective allosteric inhibition and combination therapies to overcome radiotherapy and chemotherapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Solid Tumors, Hematological Malignancies | Selectivity Assay (Need High-Purity WT G6PD and 6PGD panel) |
| Allosteric Modulators | Translational Oncology Labs | Oxidative Stress-Induced Cancers | Conformational Stability (Need Tag-free, Native-like active enzyme) |
| Combination Therapies | Pharma Partnerships | Chemoresistant Solid Tumors | Knockdown Validation (Need G6PD siRNA and Lentivirus tools) |